Jounce Therapeutics, Inc.

Symbol: JNCE




Market price today

  • 4.8670

    P/E Ratio

  • -0.0220

    PEG Ratio

  • 98.95M

    MRK Cap

  • 0.00%

    DIV Yield

Jounce Therapeutics, Inc. (JNCE) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Dr. James Patrick Allison Ph.D.
Full-time employees:141
Address:780 Memorial Drive

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.

General Outlook

In simple terms, Jounce Therapeutics, Inc. has 52.636 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 1.000% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.231%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.243%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.094% return, is a testament to Jounce Therapeutics, Inc.'s adeptness in optimizing resource deployment. Jounce Therapeutics, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.128%. Furthermore, the proficiency of Jounce Therapeutics, Inc. in capital utilization is underscored by a remarkable 0.100% return on capital employed.

Stock Prices

Jounce Therapeutics, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $1.9404, while its low point bottomed out at $1.905. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Jounce Therapeutics, Inc.'s stock market.

Liquidity Ratios

Analyzing JNCE liquidity ratios reveals its financial health of the firm. The current ratio of 836.86% gauges short-term asset coverage for liabilities. The quick ratio (804.23%) assesses immediate liquidity, while the cash ratio (638.88%) indicates cash reserves.

Current Ratio836.86%
Quick Ratio804.23%
Cash Ratio638.88%

Profitability Ratios

JNCE profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 24.49% underscores its earnings before tax deductions. The effective tax rate stands at 0.61%, revealing its tax efficiency. The net income per EBT, 99.39%, and the EBT per EBIT, 106.07%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 23.09%, we grasp its operational profitability.

Pretax Profit Margin24.49%
Effective Tax Rate0.61%
Net Income per EBT99.39%
EBT per EBIT106.07%
EBIT per Revenue23.09%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 8.37, it details the span from stock purchase to revenue. The 8 days it takes to settle debts showcases its creditor relations.

Days of Sales Outstanding804
Fixed Asset Turnover6.66
Asset Turnover0.39

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 0.54, and free cash flow per share, 0.53, depict cash generation on a per-share basis. The cash per share value, 3.67, showcases liquidity position. Lastly, the operating cash flow sales ratio, 0.34, offers insight into cash flow relative to sales.

Operating Cash Flow per Share0.54
Free Cash Flow per Share0.53
Cash per Share3.67
Operating Cash Flow Sales Ratio0.34
Free Cash Flow to Operating Cash Flow Ratio0.98
Cash Flow Coverage Ratio2.76
Short Term Coverage Ratio6.67
Capital Expenditure Coverage Ratio59.81
Dividend Paid and Capex Coverage Ratio59.81

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 4.71%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.05, we discern the balance between debt and equity financing. The long-term debt to capitalization, 3.11%, and total debt to capitalization, 5.19%, ratios shed light on its capital structure. An interest coverage of -16.48 indicates its ability to manage interest expenses.

Debt Ratio4.71%
Debt Equity Ratio0.05
Long Term Debt to Capitalization3.11%
Total Debt to Capitalization5.19%
Interest Coverage-16.48
Cash Flow to Debt Ratio2.76
Company Equity Multiplier1.16

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 1.59, provides a glimpse into top-line earnings distributed across each share. Net income per share, -0.99, reflects the portion of profit attributed to each share. The book value per share, 3.54, represents the net asset value distributed per share, while the tangible book value per share, 3.54, excludes intangible assets.

Revenue Per Share1.59
Net Income Per Share-0.99
Book Value Per Share3.54
Tangible Book Value Per Share3.54
Shareholders Equity Per Share3.54
Interest Debt Per Share0.17
Capex Per Share-0.02

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, -83,191,640, captures the company's total value, considering both debt and equity. Income quality, 0.57, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.38, gauges operational efficiency, while the research and development to revenue, 125.94%, highlights investment in innovation.

Enterprise Value-83,191,640
Income Quality0.57
Sales General and Administrative to Revenue0.38
Research and Development to Revenue125.94%
Capex to Operating Cash Flow3.18%
Capex to Revenue-1.12%
Capex to Depreciation-44.03%
Stock-Based Compensation to Revenue12.53%
Graham Number8.86
Return on Tangible Assets-23.96%
Graham Net Net3.10
Working Capital173,663,000
Tangible Asset Value183,112,000
Net Current Asset Value167,793,000
Average Payables1,884,500

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 0.53, and the price to book ratio, 0.53, reflect the market's valuation relative to the company's book value. The price to sales ratio, 1.21, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 3.63, and price to operating cash flows, 3.51, gauge market valuation against cash flow metrics.

Price Book Value Ratio0.53
Price to Book Ratio0.53
Price to Sales Ratio1.21
Price Cash Flow Ratio3.51
Price Earnings to Growth Ratio-0.02
Enterprise Value Multiple12.05
Price Fair Value0.53
Price to Operating Cash Flow Ratio3.51
Price to Free Cash Flows Ratio3.63
Price to Tangible Book Ratio0.31
Enterprise Value to Sales-1.01
Enterprise Value Over EBITDA1.66
EV to Operating Cash Flow2.88
Earnings Yield-88.77%
Free Cash Flow Yield-51.95%
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Jounce Therapeutics, Inc. (JNCE) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 4.867 in 2024.

What is the ticker symbol of Jounce Therapeutics, Inc. stock?

The ticker symbol of Jounce Therapeutics, Inc. stock is JNCE.

What is company IPO date?

IPO date of Jounce Therapeutics, Inc. is 2017-01-26.

What is company current share price?

Current share price is 1.880 USD.

What is stock market cap today?

The market cap of stock today is 98954740.000.

What is PEG ratio in 2024?

The current -0.022 is -0.022 in 2024.

What is the number of employees in 2024?

In 2024 the company has 141.